Ultragenyx Pharmaceutical Inc. (RARE) NASDAQ

36.71

+0.35(+0.96%)

Updated at July 01 12:29PM

Currency In USD

Ultragenyx Pharmaceutical Inc.

Address

60 Leveroni Court

Novato, CA 94949

United States of America

Phone

415 483 8800

Sector

Healthcare

Industry

Biotechnology

Employees

1294

First IPO Date

January 31, 2014

Key Executives

NameTitlePayYear Born
Dr. Emil D. Kakkis M.D., Ph.D.Founder, President, Chief Executive Officer & Director1.63M1960
Mr. Thomas R. KassbergChief Business Officer & Executive Vice President714,8381960
Ms. Karah Herdman Parschauer J.D.Chief Legal Officer & Executive Vice President of Corporate Affairs846,7441978
Mr. John Richard Pinion IIChief Quality Operations Officer & Executive Vice President of Translational Sciences923,9341966
Mr. Howard HornExecutive Vice President of Corporate Strategy & Chief Financial Officer947,7701979
Mr. Erik Harris M.B.A.Executive Vice President & Chief Commercial Officer985,2661970
Dr. Eric Crombez M.D.Chief Medical Officer & Executive Vice President987,6761973
Mr. Theodore A. HuizengaSenior Vice President, Corporate Controller & Principal Accounting Officer01971
Mr. Ernie W. MeyerChief Human Resources Officer & Executive Vice President01965
Mr. Vimal SrivastavaSenior Vice President of Business Development & Alliance Management01965

Description

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.